Sfoglia per Autore
T-helper (Th) 22, a newly identified lymphocyte subset, increases 1-3 months before an MS relapse and it is not sensitive to INF beta
2011-01-01 Durelli, L.; Clerico, M.; Rolla, S.; Contessa, G.; De Mercanti, S.; Cucci, A.; Novelli, F.
T-Helper (Th)22, a Newly Identified Lymphocyte Subset, Increases 1-3 Months before an MS Relapse and It Is Not Sensitive to IFN beta
2011-01-01 Durelli L; Clerico M; Rolla S; Contessa G; De Mercanti Stefania; Cucci Angele; Bardina Valentina; Di Liberto Alessandra; Uccelli Antonio; Zaffaroni Mauro; Cavalla P; Rinaldi Luciano; Comi Cristoforo; Sosso Luisa; Cavallo Roberto; Quaglino P; Novelli Franco.
JAK2 is overexpressed in human multiple sclerosis Th17 cells and stabilizes cell surface expression of IFN-gammaR2
2011-01-01 F. Novelli, R. De Palma, S. Rolla, L. Conti, M. Clerico, G. Contessa, O. Silveinnonen and L. Durelli.
DNA vaccination with alpha-enolase effectively prolongs survival in amouse model of human pancreatic cancer.
2011-01-01 Paola Cappello; Simona Rolla; Roberta Curto; Helen Carnevale; Roberto Chiarle; Federica Cavallo; Mirella Giovarelli; Francesco Novelli
CHARACTERIZATION OF AUTOREACTIVE TCR REPERTOIRE IN PATIENTS AFFECTED BYMULTIPLE SCLEROSIS.
2011-01-01 Simona Rolla; Gabriele Di Sante; Marinella Clerico; Chiara Nicolò; Agata Katia Patanella; Antonio Amoroso; Maria Edvige Fasano; Anna Paola Batocchi; Francesco Ria; Francesco Novelli
Circulating T helper 22 cells increase in multiple sclerosis patients:phenotypical and functional characterization.
2011-01-01 Simona Rolla ; Marinella Clerico; Valentina Bardina; Paola Bonaventura; Pietro Quaglino; Giulia Contessa; Luca Durelli; Francesco Novelli
JAK2 is overexpressed in human multiple sclerosis Th17 cells andstabilizes cell surface expression of IFN-gammaR2.
2011-01-01 De Palma R; Conti L; Rolla S; Boselli D; Rodolico G; Silveinnonen O; Clerico M; Contessa G; Durelli L; Novelli F
T Regulatories (Tregs) and suppressor cytokine mRNA (IL-10, TGF-beta, IL-27) increase after Alemtuzumab in MS: First 25 Month Immunological Report on 323 and 324 Genzyme trials
2012-01-01 De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Kovarova,I.; Clerico, M.; Durelli, L.
Phenotypical and functional characterization of T Helper 22 cells inMultiple Sclerosis patients
2012-01-01 S. Rolla; M. Clerico; V. Bardina; P. Quaglino; L. Durelli; F. Novelli
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials
2012-01-01 De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L.
Multiparametric analysis of Th17 and Th22 cells discloses their pathogenicity in human multiple sclerosis
2012-01-01 Rolla, S.; Bardina, V.; Clerico, M.; Durelli L. and Novelli F.
Th17 Cells in Multiple Sclerosis Express Higher Levels of JAK2, Which Increases Their Surface Expression of IFN-γR2
2012-01-01 Conti L; De Palma R; Rolla S; Boselli D; Rodolico G; Kaur S; Silvennoinen O; Niccolai E; Amedei A; Ivaldi F; Clerico M; Contessa G; Uccelli A; Durelli L; Novelli F.
Does Th17 response be harnessed by the antigen DNAvaccination against pancreatic adenocarcinomas?
2012-01-01 P. Cappello; S Rolla; R Curto; A. Ferrabone; E.C. Ramesh; H Carnevale; M Giovarelli; F Novelli
THE ACUTE-PHASE PROTEIN HEMOPEXIN IS A NEGATIVE REGULATOR OF TH17 RESPONSE AND EXPERIMENTAL AUTOIMMUNE ENCEPHALOMIELITIS DEVELOPMENT
2013-01-01 Rolla S.; Ingoglia G.; Bardina V.; Silengo L.; Altruda F.; Novelli F.; Tolosano E.
Role of Th22 expansion in multiple sclerosis disease activity
2013-01-01 De Mercanti S; Clerico M; Rolla S; Bardina V; Quaglino P; De Palma R; Gned D; Novelli F; Durelli L
Vaccination with ENO1 DNA Prolongs Survival of Genetically Engineered Mice with Pancreatic Cancer.
2013-01-01 Cappello P; Rolla S; Chiarle R; Principe M; Cavallo F; Perconti G; Feo S; Giovarelli M; Novelli F.
Treg Cell Function and Related Cytokines and Chemokines Changes during Alemtuzumab Treatment: a 24 Months Immunological Study
2013-01-01 De Mercanti S; Clerico M; Rolla S; Cucci A; Novelli F; Taverna D; Bardina V; Piazza F; Gibbin M; Vargas J; Vladic A; Habek M; Adamec B; Brinar V; Cocco E; Frau J; Annovazzi P; Horakova D; Kovarova I; Durelli L
How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study
2014-01-01 S De Mercanti ; M Clerico ; S Rolla ; V Bardina ; M.A Cucci ; D Taverna ; D Cimino ; F Piazza ; E Virgilio ; D Armocida ; M Basso ; A Vladic ; M Habek ; I Adamec ; V Brinar ; E Cocco ; J Frau ; P Annovazzi ; D Horàkovà ; I Kovàrovà ; F Novelli ; L Durelli
Chimeric Rat/Human HER2 Efficiently Circumvents HER2 Tolerance in Cancer Patients.
2014-01-01 Occhipinti S; Sponton L; Rolla S; Caorsi C; Novarino A; Donadio M; Bustreo S; Satolli MA; Pecchioni C; Marchini C; Amici A; Cavallo F; Cappello P; Pierobon D; Novelli F; Giovarelli M.
Th22 cells are expanded in multiple sclerosis and are resistant to IFN-
2014-01-01 S. Rolla;V. Bardina;S. De Mercanti;P. Quaglino;R. De Palma;D. Gned;D. Brusa;L. Durelli;F. Novelli;M. Clerico
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| T-helper (Th) 22, a newly identified lymphocyte subset, increases 1-3 months before an MS relapse and it is not sensitive to INF beta | 2011 | Durelli, L.; Clerico, M.; Rolla, S.; Contessa, G.; De Mercanti, S.; Cucci, A.; Novelli, F. | |
| T-Helper (Th)22, a Newly Identified Lymphocyte Subset, Increases 1-3 Months before an MS Relapse and It Is Not Sensitive to IFN beta | 2011 | Durelli L; Clerico M; Rolla S; Contessa G; De Mercanti Stefania; Cucci Angele; Bardina Valentina; Di Liberto Alessandra; Uccelli Antonio; Zaffaroni Mauro; Cavalla P; Rinaldi Luciano; Comi Cristoforo; Sosso Luisa; Cavallo Roberto; Quaglino P; Novelli Franco. | |
| JAK2 is overexpressed in human multiple sclerosis Th17 cells and stabilizes cell surface expression of IFN-gammaR2 | 2011 | F. Novelli, R. De Palma, S. Rolla, L. Conti, M. Clerico, G. Contessa, O. Silveinnonen and L. Durelli. | |
| DNA vaccination with alpha-enolase effectively prolongs survival in amouse model of human pancreatic cancer. | 2011 | Paola Cappello; Simona Rolla; Roberta Curto; Helen Carnevale; Roberto Chiarle; Federica Cavallo; Mirella Giovarelli; Francesco Novelli | |
| CHARACTERIZATION OF AUTOREACTIVE TCR REPERTOIRE IN PATIENTS AFFECTED BYMULTIPLE SCLEROSIS. | 2011 | Simona Rolla; Gabriele Di Sante; Marinella Clerico; Chiara Nicolò; Agata Katia Patanella; Antonio Amoroso; Maria Edvige Fasano; Anna Paola Batocchi; Francesco Ria; Francesco Novelli | |
| Circulating T helper 22 cells increase in multiple sclerosis patients:phenotypical and functional characterization. | 2011 | Simona Rolla ; Marinella Clerico; Valentina Bardina; Paola Bonaventura; Pietro Quaglino; Giulia Contessa; Luca Durelli; Francesco Novelli | |
| JAK2 is overexpressed in human multiple sclerosis Th17 cells andstabilizes cell surface expression of IFN-gammaR2. | 2011 | De Palma R; Conti L; Rolla S; Boselli D; Rodolico G; Silveinnonen O; Clerico M; Contessa G; Durelli L; Novelli F | |
| T Regulatories (Tregs) and suppressor cytokine mRNA (IL-10, TGF-beta, IL-27) increase after Alemtuzumab in MS: First 25 Month Immunological Report on 323 and 324 Genzyme trials | 2012 | De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Kovarova,I.; Clerico, M.; Durelli, L. | |
| Phenotypical and functional characterization of T Helper 22 cells inMultiple Sclerosis patients | 2012 | S. Rolla; M. Clerico; V. Bardina; P. Quaglino; L. Durelli; F. Novelli | |
| Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials | 2012 | De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L. | |
| Multiparametric analysis of Th17 and Th22 cells discloses their pathogenicity in human multiple sclerosis | 2012 | Rolla, S.; Bardina, V.; Clerico, M.; Durelli L. and Novelli F. | |
| Th17 Cells in Multiple Sclerosis Express Higher Levels of JAK2, Which Increases Their Surface Expression of IFN-γR2 | 2012 | Conti L; De Palma R; Rolla S; Boselli D; Rodolico G; Kaur S; Silvennoinen O; Niccolai E; Amedei A; Ivaldi F; Clerico M; Contessa G; Uccelli A; Durelli L; Novelli F. | |
| Does Th17 response be harnessed by the antigen DNAvaccination against pancreatic adenocarcinomas? | 2012 | P. Cappello; S Rolla; R Curto; A. Ferrabone; E.C. Ramesh; H Carnevale; M Giovarelli; F Novelli | |
| THE ACUTE-PHASE PROTEIN HEMOPEXIN IS A NEGATIVE REGULATOR OF TH17 RESPONSE AND EXPERIMENTAL AUTOIMMUNE ENCEPHALOMIELITIS DEVELOPMENT | 2013 | Rolla S.; Ingoglia G.; Bardina V.; Silengo L.; Altruda F.; Novelli F.; Tolosano E. | |
| Role of Th22 expansion in multiple sclerosis disease activity | 2013 | De Mercanti S; Clerico M; Rolla S; Bardina V; Quaglino P; De Palma R; Gned D; Novelli F; Durelli L | |
| Vaccination with ENO1 DNA Prolongs Survival of Genetically Engineered Mice with Pancreatic Cancer. | 2013 | Cappello P; Rolla S; Chiarle R; Principe M; Cavallo F; Perconti G; Feo S; Giovarelli M; Novelli F. | |
| Treg Cell Function and Related Cytokines and Chemokines Changes during Alemtuzumab Treatment: a 24 Months Immunological Study | 2013 | De Mercanti S; Clerico M; Rolla S; Cucci A; Novelli F; Taverna D; Bardina V; Piazza F; Gibbin M; Vargas J; Vladic A; Habek M; Adamec B; Brinar V; Cocco E; Frau J; Annovazzi P; Horakova D; Kovarova I; Durelli L | |
| How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study | 2014 | S De Mercanti ; M Clerico ; S Rolla ; V Bardina ; M.A Cucci ; D Taverna ; D Cimino ; F Piazza ; E Virgilio ; D Armocida ; M Basso ; A Vladic ; M Habek ; I Adamec ; V Brinar ; E Cocco ; J Frau ; P Annovazzi ; D Horàkovà ; I Kovàrovà ; F Novelli ; L Durelli | |
| Chimeric Rat/Human HER2 Efficiently Circumvents HER2 Tolerance in Cancer Patients. | 2014 | Occhipinti S; Sponton L; Rolla S; Caorsi C; Novarino A; Donadio M; Bustreo S; Satolli MA; Pecchioni C; Marchini C; Amici A; Cavallo F; Cappello P; Pierobon D; Novelli F; Giovarelli M. | |
| Th22 cells are expanded in multiple sclerosis and are resistant to IFN- | 2014 | S. Rolla;V. Bardina;S. De Mercanti;P. Quaglino;R. De Palma;D. Gned;D. Brusa;L. Durelli;F. Novelli;M. Clerico |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile